NCT07548177 Anlotinib Dihydrochloride Alveolar Soft Part Sarcoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07548177 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 3 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why NCT07548177 is a hot trial to watch
Alveolar Soft Part Sarcoma is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07548177 is notable because it evaluates Anlotinib Dihydrochloride in a Phase 2 design sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07548177 |
| Official title | Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma |
| Phase / status | Phase 2 / Recruiting |
| Intervention | Anlotinib Dihydrochloride |
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Geography | China |
| Enrollment | [object Object] |
| Primary endpoint | Objective response rate (IRC assessment) |
| Endpoint time frame | The period from baseline to the end of the trial is expected to be 32 months. |
| Primary completion / readout proxy | [object Object] |
Protocol design and endpoint interpretation
This is a Phase II, single-arm, multicenter clinical study aimed at demonstrating the effectiveness of benmelstobart injection combined with anlotinib hydrochloride capsules in patients aged 14 years or older with advanced or unresectable alveolar soft part sarcoma by evaluating the objective response rate (IRC).
Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment. Planned enrollment of [object Object] participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Objective response rate (IRC assessment) (The period from baseline to the end of the trial is expected to be 32 months.) — The proportion of patients with tumor volume reduction reaching 30% is usually the sum of the proportions of complete response (CR) and partial response (PR). (IRC Assessment)
Readout outlook and evidence gap
The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Anlotinib Dihydrochloride is indexed as Small molecule drug, with target FGFRs x VEGFR1 x VEGFR2 x VEGFR3 x c-Kit, mechanism FGFRs antagonists, VEGFR1 antagonists, VEGFR2 antagonists, and global highest development status Approved.
Company & Deal Intelligence MCP profile: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is resolved to a normalized organization record in Lianyungang, China. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
NCT07548177 provides a focused lens on Alveolar Soft Part Sarcoma development. Its value will be determined by whether Anlotinib Dihydrochloride can convert the current Phase 2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
